Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratificationLung cancer, Baseline biopsies, Prognostic immune checkpoint combinations, Pan-cancerBackground Permanence of front-line management of lung cancer ...
Cisplatin-based adjuvant chemotherapy currently constitutes the standard-of-care after curative surgery for stage IIA-IIIB resected non-small cell lung cancer (NSCLC)1,2. However, the 5-year survival rate still remains unsatisfactory, with alarming levels of grade 3 toxicity observed in more than 6...
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers PURPOSE: Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancer... K Bergethon,A Shaw,Ou, SHI,... - 《Journal of Clinical Oncology》 ...
Rizvi, N.A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer.Science348, 124–128 (2015). ArticleCASPubMedPubMed CentralGoogle Scholar Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma.N. Engl. J. Med...
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128. 6. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015; 372: 2018-2028. 7. Herbst RS, Baas P, ...
Our data support the notion that the higher EVs concentrations seen in cancer patients versus healthy controls perhaps result from a systemic, non-tumor origin instead of cancer cell-produced vesicles. An interesting observation from our work is the preferential enrichment of tRNA sequences in the ...
Therefore, DDRs are considered promising therapeutic targets in various cancer types, and several small molecules kinase inhibitors of DDRs have been developed [24,25,26]. Prostate cancer (PCa) is the most commonly diagnosed non-skin malignant neoplasia in males in the United States [27]. ...
(65.4) non-GTR 17 (32.7) n.a 1 (1.9) Adjuvant therapy no 9 (17.3) RTX 14 (26.9) CTX 5 (9.6) RTX and CTX 24 (46.1) WHO grade grade II 18 (34.6) grade III 34 (65.4) TNC positive 46 (88.5) negative 6 (11.5) LAMA2 positive 28 (53.8) negative 24 (46.2) Chromosome 1q ...
If LgR5 marks stem cells, there are many of LgR5 negative non-stem cells, which are nevertheless cycling. Therefore a combination of clonal selection and cancer stem cell model, as previously suggested by others [8, 34] might be applied. Moreover, we found a small subpopulation of cells ...
When we segregated survival on the basis of functional, immune and combined fitness in TCGA and a cohort of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD-1 at MSKCC (Extended Data Fig. 9), we found that functional and immune fitness components were required to ...